and disabling issue for military veterans, particularly 
those who have been deployed in war zones. 
(11) FGIMDs affect individuals of all ages in-
cluding children, and pediatric FGIMDs can be par-
ticularly serious, leading to a lifetime of painful 
symptoms and medical expenses associated with 
management of chronic illness or death. 
(12) There is inadequate public education and 
misunderstanding of FGIMDs leading to stigma 
placed upon individuals so afflicted. 
(13) The National Institutes of Health’s Na-
tional Commission on Digestive Diseases identified 
comprehensive research goals related to FGIMDs in 
its April 2009 report to Congress and the American 
public entitled ‘‘Opportunities and Challenges in Di-
gestive Diseases Research: Recommendations of the 
National Commission on Digestive Diseases’’. 
SEC. 3. FUNCTIONAL GASTROINTESTINAL AND MOTILITY 
DISORDERS RESEARCH ENHANCEMENT. 
Part B of the title IV of the Public Health Service 
Act (42 U.S.C. 284 et seq.) is amended by adding at the 
end the following: 
VerDate Sep 11 2014 
03:50 May 16, 2015
Jkt 049200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H2311.IH
H2311
emcdonald on DSK67QTVN1PROD with BILLS
‘‘SEC. 409K. FUNCTIONAL GASTROINTESTINAL AND MOTIL-
ITY DISORDERS. 
‘‘The Director of NIH may expand, intensify, and co-
ordinate the activities of the National Institutes of Health 
with respect to functional gastrointestinal and motility dis-
orders (in this section referred to as ‘FGIMDs’) by— 
‘‘(1) expanding basic and clinical research into 
FGIMDs 
by 
implementing 
the 
research 
rec-
ommendations of the National Commission on Di-
gestive Diseases relating to FGIMDs; 
‘‘(2) providing support for the establishment of 
up to five centers of excellence on FGIMDs at lead-
ing academic medical centers throughout the country 
to carry out innovative basic, translational, and clin-
ical research focused on FGIMDs; 
‘‘(3) supporting innovative approaches to edu-
cating health care providers and patients regarding 
strategies that improve patient-provider relationships 
and care and foster research to determine the effects 
of these approaches in improving patient satisfac-
tion, improved clinical outcomes, efficient utilization 
of health care services, and reduced health care 
costs; 
‘‘(4) exploring collaborative research opportuni-
ties among the National Institute of Diabetes and 
Digestive and Kidney Diseases, the Office of Re-
VerDate Sep 11 2014 
23:45 May 15, 2015
Jkt 049200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H2311.IH
H2311
emcdonald on DSK67QTVN1PROD with BILLS
search on Women’s Health, the Office of Rare Dis-
ease Research, and other Institutes and Centers of 
the National Institutes of Health; 
‘‘(5) directing the National Institute of Diabe-
tes and Digestive and Kidney Diseases to provide 
the necessary funding for continued expansion and 
advancement of the FGIMDs research portfolio 
through intramural and extramural research; 
‘‘(6) directing the National Institute of Diabe-
tes and Digestive and Kidney Diseases and the Eu-
nice Kennedy Shriver National Institute of Child 
Health and Human Development to expand research 
into FGIMDs that impact children, such as 
Hirschsprung’s disease and cyclic vomiting syn-
drome, and maternal health, such as fecal inconti-
nence; and 
‘‘(7) exploring opportunities to partner with the 
Department of Defense and the Department of Vet-
erans Affairs to increase research and improve pa-
tient care regarding FGIMDs that commonly impact 
veterans and active duty military personnel, such as 
IBS and dyspepsia.’’. 
VerDate Sep 11 2014 
23:45 May 15, 2015
Jkt 049200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H2311.IH
H2311
emcdonald on DSK67QTVN1PROD with BILLS
SEC. 4. PROMOTING PUBLIC AWARENESS OF FUNCTIONAL 
GASTROINTESTINAL 
AND 
MOTILITY 
DIS-
ORDERS. 
Part B of title III of the Public Health Service Act 
(42 U.S.C. 243 et seq.) is amended by adding at the end 
the following: 
‘‘SEC. 320B. PUBLIC AWARENESS OF FUNCTIONAL GASTRO-
INTESTINAL AND MOTILITY DISORDERS. 
‘‘The Secretary may engage in public awareness and 
education activities to increase understanding and recogni-
tion of functional gastrointestinal and motility disorders 
(in this section referred to as ‘FGIMDs’). Such activities 
may include the distribution of print, film, and web-based 
materials targeting health care providers and the public 
and prepared and disseminated in conjunction with pa-
tient organizations that treat FGIMDs. The information 
expressed through such activities should emphasize— 
‘‘(1) basic information on FGIMDs, their symp-
toms, prevalence, and frequently co-occurring condi-
tions; and 
‘‘(2) the importance of early diagnosis, and 
prompt and accurate treatment of FGIMDs.’’. 
VerDate Sep 11 2014 
23:45 May 15, 2015
Jkt 049200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H2311.IH
H2311
emcdonald on DSK67QTVN1PROD with BILLS
SEC. 5. SENSE OF CONGRESS OF THE DEVELOPMENT AND 
OVERSIGHT OF INNOVATIVE TREATMENT OP-
TIONS FOR FUNCTIONAL GASTROINTESTINAL 
AND MOTILITY DISORDERS. 
It is the sense of Congress that, considering the cur-
rent lack of effective treatment options for the global 
symptoms of functional gastrointestinal and motility dis-
orders (in this section referred to as ‘‘FGIMDs’’) and the 
inherent challenges of developing and bringing such treat-
ments to market, the Commissioner of Food and Drugs 
should continue and accelerate important efforts to im-
prove the development and oversight of treatment options 
for FGIMDs by— 
(1) enhancing the commitment to emerging ef-
forts like the Patient Reported Outcomes Consor-
tium to expedite medical device and drug develop-
ment, study appropriate balances between risk and 
patient benefit, and identify proper endpoints for 
conditions without clear, biological indicators; 
(2) enhancing the commitment to broad efforts 
like the Critical Path Initiative focused on ensuring 
that scientific breakthroughs are quickly translated 
into safe and beneficial treatment options; and 
(3) continuing collaboration with patient and 
provider organizations that treat FGIMDs so that 
VerDate Sep 11 2014 
23:45 May 15, 2015
Jkt 049200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H2311.IH
H2311
emcdonald on DSK67QTVN1PROD with BILLS
the patient perspective is considered when deter-
mining the need for innovative treatments. 
Æ 
VerDate Sep 11 2014 
23:45 May 15, 2015
Jkt 049200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6301
E:\BILLS\H2311.IH
H2311
emcdonald on DSK67QTVN1PROD with BILLS